We are live on ! Find out more
Loomis, Sayles & Company

Loomis, Sayles & Company Portfolio holdings

AUM $74.3B
1-Year Est. Return 24.01%
This Fund
S&P 500
This Quarter Est. Return
+12.4%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$68.7B
AUM Growth
+$6.42B
Cap. Flow
+$916M
Cap. Flow %
1.33%
Top 10 Hldgs %
43.14%
Holding
753
New
67
Increased
309
Reduced
220
Closed
106

Sector Composition

Rank Sector Weight
1 Technology 27.5%
2 Consumer Discretionary 17.68%
3 Communication Services 12.47%
4 Healthcare 12.12%
5 Industrials 9.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SKY icon
226
Champion Homes
SKY
$5.1B
$19.7M 0.03%
737,556
+47,462
+7% +$1.29M
ARGX icon
227
argenx
ARGX
$54.8B
$19.6M 0.03%
74,789
-11,790
-14% -$2.83M
NBIX icon
228
Neurocrine Biosciences
NBIX
$15.9B
$19.6M 0.03%
203,399
+17,892
+10% +$2.07M
CRL icon
229
Charles River Laboratories
CRL
$13.6B
$19.5M 0.03%
86,326
-31,903
-27% -$6.62M
EEFT icon
230
Euronet Worldwide
EEFT
$2.66B
$19.5M 0.03%
214,566
+17,167
+9% +$1.67M
SUI icon
231
Sun Communities
SUI
$14.4B
$19.5M 0.03%
138,481
+13,519
+11% +$1.94M
ASND icon
232
Ascendis Pharma A/S
ASND
$16.8B
$19.3M 0.03%
125,010
-1,380
-1% -$198K
MORN icon
233
Morningstar
MORN
$7.41B
$19.1M 0.03%
119,193
-1,330
-1% -$210K
HEI icon
234
HEICO Corp
HEI
$52.1B
$19.1M 0.03%
182,713
-1,900
-1% -$196K
DRNA
235
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$19M 0.03%
1,058,455
+333,452
+46% +$6.9M
AVLR
236
DELISTED
Avalara, Inc.
AVLR
$18.6M 0.03%
146,411
+8,278
+6% +$1.05M
JAZZ icon
237
Jazz Pharmaceuticals
JAZZ
$16.2B
$18.5M 0.03%
129,468
+20,422
+19% +$2.53M
TECH icon
238
Bio-Techne
TECH
$11.3B
$18.3M 0.03%
295,784
+43,924
+17% +$2.86M
BKLN icon
239
Invesco Senior Loan ETF
BKLN
$6.75B
$18.2M 0.03%
+835,000
New +$18.1M
SMTC icon
240
Semtech
SMTC
$13B
$17.9M 0.03%
338,275
+23,748
+8% +$1.33M
ASH icon
241
Ashland
ASH
$3.42B
$17.6M 0.03%
248,449
+130,503
+111% +$9.67M
GMED icon
242
Globus Medical
GMED
$11.5B
$17.5M 0.03%
353,093
-3,712
-1% -$191K
CLVT icon
243
Clarivate
CLVT
$1.19B
$17.3M 0.03%
558,526
+40,178
+8% +$1.09M
ESE icon
244
ESCO Technologies
ESE
$7.78B
$17M 0.02%
211,585
-2,194
-1% -$189K
GRA
245
DELISTED
W.R. Grace & Co.
GRA
$16.9M 0.02%
420,100
+16,868
+4% +$769K
SPHR icon
246
Sphere Entertainment
SPHR
$6.29B
$16.9M 0.02%
246,034
+12,398
+5% +$894K
LSXMK
247
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
$16.8M 0.02%
654,869
+60,051
+10% +$1.63M
MNTV
248
DELISTED
Momentive Global Inc. Common Stock
MNTV
$16.4M 0.02%
+743,738
New +$17.3M
SRI icon
249
Stoneridge
SRI
$197M
$16.1M 0.02%
877,552
+16,713
+2% +$341K
DAR icon
250
Darling Ingredients
DAR
$10B
$16M 0.02%
444,474
-66,839
-13% -$2.04M

Similar funds

Loomis, Sayles & Company's Q3 2020 Portfolio in Review

As of Q3 2020, Loomis, Sayles & Company held 753 positions worth $68.7B, up 10% from $62.3B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Loomis, Sayles & Company's Q3 2020 filing shows 67 new, 309 increased, 220 reduced and 106 closed positions. Its largest new stake was Wells Fargo 7.5% Non Cumv Perp Conv: 440,814 shares worth $10.4M. The largest sale was Amazon, an estimated $389M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 27% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • Loomis, Sayles & Company's largest Q3 2020 buy was Wells Fargo 7.5% Non Cumv Perp Conv: 440,814 shares worth $10.4M.
  • Loomis, Sayles & Company added most to Illumina in Q3 2020, an estimated $454M increase.
  • Loomis, Sayles & Company's biggest Q3 2020 reduction was Amazon, cutting an estimated $389M.
  • Loomis, Sayles & Company fully exited Cogent Communications in Q3 2020, selling an estimated $50.6M.
  • Loomis, Sayles & Company's ten largest holdings make up 43% of its $68.7B portfolio in Q3 2020.
  • Loomis, Sayles & Company opened 67 new positions and closed 106 in Q3 2020.
  • Loomis, Sayles & Company's portfolio value rose 10% quarter-over-quarter to $68.7B.

Based on Loomis, Sayles & Company's 13F filing for Q3 2020, filed 12 Nov 2020.